title: Uneventful splenectomy and cholecystectomy in a patient treated with anti-interleukin-6 receptor antibody therapy.
abstract: BACKGROUND
  Interleukin-6 (IL-6) is a multifunctional cytokine that regulates various aspects of the immune responses, acute phase reactions, and hematopoiesis. In rodent models, IL-6 has been suggested to be one of the essential mediators for optimal acute phase responses to infection and tissue damage. However, in humans, the roles of IL-6 in acute phase responses after surgery remain poorly understood.
  
  
  METHODS
  We present the first case report of successful splenectomy and cholecystectomy in a severe autoimmune-associated hemolytic anemia patient during treatment with a humanized anti-IL-6 receptor antibody.
  
  
  CONCLUSIONS
  This unique case suggests that IL-6 is not an essential cytokine to safely perform surgical intervention and to prevent postoperative complications and that surgical intervention may not be contraindicated but can be selected as a therapeutic modality in patients treated with anti-IL-6 receptor antibody therapy.
authors: Department of Surgery, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan.
authors: Morihiko
authors: M
authors: Ishizaki
authors: Tetsuro
authors: T
authors: Sasada
authors: Akane
authors: A
authors: Kunitomi
authors: Yoshiteru
authors: Y
authors: Konaka
authors: Masato
authors: M
authors: Yagita
authors: Shutaro
authors: S
authors: Gunji
authors: Michiyuki
authors: M
authors: Kanai
authors: Norihiro
authors: N
authors: Nishimoto
authors: Arimichi
authors: A
authors: Takabayashi
mesh_terms: D000208:Acute Disease; D000328:Adult; D000744:Anemia, Hemolytic, Autoimmune / Q000188:drug therapy*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002763:Cholecystectomy; D002764:Cholecystitis / Q000601:surgery; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D042882:Gallstones / Q000601:surgery*; D006801:Humans; D008297:Male; D019947:Receptors, Interleukin-6 / Q000037:antagonists & inhibitors*; D013156:Splenectomy; D013163:Splenomegaly / Q000601:surgery*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C508603:IL6R protein, human; D019947:Receptors, Interleukin-6; C502936:tocilizumab
references: Arthritis Rheum. 2004 Jun;50(6):1761-9
references: 15188351
references: Nat Clin Pract Rheumatol. 2006 Nov;2(11):619-26
references: 17075601
references: Blood. 2005 Oct 15;106(8):2627-32
references: 15998837
references: Nature. 1994 Mar 24;368(6469):339-42
references: 8127368
references: Int J Hematol. 2004 Oct;80(3):246-9
references: 15540899
references: Arthritis Rheum. 2005 Mar;52(3):818-25
references: 15751095
references: FASEB J. 2000 Dec;14(15):2525-31
references: 11099471
references: Gastroenterology. 2004 Apr;126(4):989-96; discussion 947
references: 15057738
references: Clin Immunol Immunopathol. 1989 Mar;50(3):399-401
references: 2465111